uniQure N.V. - 8-K Filing
uniQure reports Q3 2026 revenue of $5.2M and announces FDA Priority Review for Huntington’s disease therapy AMT-130 with PDUFA date of May 1, 2027 (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $QURE
Read the full article at SEC EDGAR
Part of the story InMode Reports Q3 2026 Financial Results with Stable Revenue and Reaffirmed Outlook (23 articles)